VTGN Vistagen Therapeutics, Inc.

VistaGen Therapeutics Inc is a clinical-stage biopharmaceutical company that develops and commercializes product candidates for patients with central nervous system diseases. Its product AV-101 is currently being evaluated in a Phase 2 monotherapy study.

$0.16  +0.01 (5.52%)
As of 10/03/2022 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/06/2016
Outstanding shares:  206,836,345
Average volume:  12,013,145
Market cap:   $31,459,808
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BQ1KSF1
Valuation   (See tab for details)
PE ratio:   -0.54
PB ratio:   0.41
PS ratio:   20.81
Return on equity:   -46.62%
Net income %:   -2,466.10%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy